Literature DB >> 15146170

Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2alpha.

Seiji Sumigama1, Tomomi Ito, Hiroaki Kajiyama, Kiyosumi Shibata, Koji Tamakoshi, Fumitaka Kikkawa, Trevor Williams, Michael A Tainsky, Seiji Nomura, Shigehiko Mizutani.   

Abstract

A previous report demonstrated that AP-2alpha favors the survival of ovarian cancer patients by clinical findings. However, the functional roles of AP-2alpha in human ovarian cancers have not been determined. To clarify the roles, we overexpressed AP-2alpha in SKOV3 human ovarian cancer cells, which originally possess little AP-2alpha. AP-2alpha overexpression changed cell morphology from spindle to epithelioid type and suppressed cell proliferation and invasion, which would be partially correlated with decreased phosphorylation levels of the erbB2, Akt and ERK pathways, increased E-cadherin and reduced pro-matrix metalloproteinase-2 levels. Moreover, nude mice intraperitoneally injected with AP-2alpha-overexpressing cells survived longer than those with neo-transfected cells. The present data represent the first direct evidence that AP-2alpha plays a tumor suppressive role in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15146170     DOI: 10.1038/sj.onc.1207723

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  AP-2α-dependent regulation of Bcl-2/Bax expression affects apoptosis in the trophoblast.

Authors:  Ling Zhang; Liting Jia; Shihong Cui; Ying Shi; Aimin Chang; Peng Wang; Zhan Zhang
Journal:  J Mol Histol       Date:  2012-08-11       Impact factor: 2.611

2.  Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells.

Authors:  Peter B Makhov; Konstantin V Golovine; Alexander Kutikov; Daniel J Canter; Vera A Rybko; Dmitry A Roshchin; Vsevolod B Matveev; Robert G Uzzo; Vladimir M Kolenko
Journal:  Carcinogenesis       Date:  2011-09-22       Impact factor: 4.944

3.  Silencing of lncRNA DLEU1 inhibits tumorigenesis of ovarian cancer via regulating miR-429/TFAP2A axis.

Authors:  Huiying Xu; Lingyan Wang; Xiuli Jiang
Journal:  Mol Cell Biochem       Date:  2020-11-10       Impact factor: 3.396

4.  Identification and Functional Validation of Differentially Expressed microRNAs in Ascites-Derived Ovarian Cancer Cells Compared with Primary Tumour Tissue.

Authors:  Yahui Jiang; Yiwen Shi; Tianjiao Lyu; Hua Liu; Lifei Shen; Tianyu Zhou; Weiwei Feng
Journal:  Cancer Manag Res       Date:  2021-08-21       Impact factor: 3.989

5.  Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.

Authors:  Brandi R Whitley; Lea M Beaulieu; Jennifer C Carter; Frank C Church
Journal:  Gynecol Oncol       Date:  2006-10-30       Impact factor: 5.482

6.  Specificity protein 1 (Sp1) maintains basal epithelial expression of the miR-200 family: implications for epithelial-mesenchymal transition.

Authors:  Natasha Kolesnikoff; Joanne L Attema; Suraya Roslan; Andrew G Bert; Quenten P Schwarz; Philip A Gregory; Gregory J Goodall
Journal:  J Biol Chem       Date:  2014-03-13       Impact factor: 5.157

7.  Identification of Tumor Microenvironment-Related Prognostic Biomarkers for Ovarian Serous Cancer 3-Year Mortality Using Targeted Maximum Likelihood Estimation: A TCGA Data Mining Study.

Authors:  Lu Wang; Xiaoru Sun; Chuandi Jin; Yue Fan; Fuzhong Xue
Journal:  Front Genet       Date:  2021-06-03       Impact factor: 4.599

8.  Activating enhancer-binding protein-2α induces cyclooxygenase-2 expression and promotes nasopharyngeal carcinoma growth.

Authors:  Dingbo Shi; Xiangsheng Xiao; Yun Tian; Lijun Qin; Fangyun Xie; Rui Sun; Jingshu Wang; Wenbin Li; Tianze Liu; Yao Xiao; Wendan Yu; Wei Guo; Yuqing Xiong; Huijuan Qiu; Tiebang Kang; Wenlin Huang; Chong Zhao; Wuguo Deng
Journal:  Oncotarget       Date:  2015-03-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.